ArticleTransboundary and emerging diseases2026
First Report of Human Infection Caused by Aspergillus steynii and Analysis of Its Whole-Genome Characteristics.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First Report of Human Infection Caused by Aspergillus steynii and Analysis of Its Whole-Genome Characteristics.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The incidence of infections caused by rare pathogens has increased in recent years. This necessitates the development of effective diagnostic and therapeutic approaches. In this study, we report the first documented case of Aspergillus steynii-induced pulmonary infection in humans. We evaluated the morphological and molecular characteristics of this fungus to elucidate its role in human infections. A 47-year-old woman with immunosuppression after bone marrow transplantation developed symptoms of pulmonary infection. The pathogen was identified as A. steynii through culture techniques, microscopy, mass spectrometry, multigene molecular identification, and whole-genome sequencing. Antifungal susceptibility testing was performed, and comparative genomic analysis was conducted to assess the phylogenetic relationship and genomic characteristics of A. steynii and other pathogenic Aspergillus species. Genomic analysis revealed a high degree of similarity with other pathogenic Aspergillus species. Furthermore, we identified 470 unique gene families primarily associated with ABC transporter pathways linked to multidrug resistance. The strain was sensitive to triazoles and echinocandins but exhibited elevated minimum inhibitory concentrations (MICs) for amphotericin B, flucytosine, and fluconazole. In addition, multiple potential drug resistance genes were identified, indicating the potential for multidrug resistance. The emergence of A. steynii in humans poses new clinical challenges and risks, including cross-species transmission and multidrug resistance. The potential for A. steynii infections, particularly in immunosuppressed patients, highlights the importance of early diagnosis and timely intervention to reduce the risk of misdiagnosis or delayed treatment. Thus, our findings have the potential to improve the clinical and differential diagnosis of this infection and facilitate the development of effective therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.